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ABSTRACT 
Postmortem diagnosis of fatal intoxications is complicated. Autopsy findings indicative of an 
intoxication related death are scarce and mostly unspecific. Instead, the diagnosis is more 
dependent on the circumstances surrounding death, and on the toxicological results. In order 
to correctly evaluate the toxicological results, the forensic investigator needs to know the 
concentrations of various substances that can be considered “normal” and which 
concentrations that may be “lethal”. While a wealth of scientific data exist concerning 
concentrations and effects in experimental animals and in living human subjects, these data 
cannot simply be translated into postmortem concentrations. Due to various changes 
occurring already in the early phase after death, the blood postmortem concentration of a 
substance postmortem often does not mirror the concentration antemortem. In order to 
correctly evaluate postmortem toxicological results there is a need for postmortem reference 
values, allowing for the separation between the lethal and non-lethal concentrations. 
Toxicological data based on the analysis of whole blood from the femoral vein collected at 
autopsies conducted between 1992 and 2010 were used to establish multiple categories of 
reference concentrations; Group A (intoxications with a single substance only), Group B 
(mixed intoxications) and Group C (controls). A well-defined automated selection process 
followed by a standardized multi-reviewer process and a case-by-case evaluation were 
applied to generate reference values for each group. 
Paper I-IV present postmortem reference concentrations of 48 substances. In most cases there 
are separate reference concentrations for different types of intoxications (group A and group 
B) as well as controls (group C). In general, there is a substantial overlap in concentrations 
between the two intoxication groups, whereas the controls often show much lower levels. 
In addition to the establishment of postmortem reference concentrations the different studies 
included in this thesis provide some additional information. Paper I presents a fatal toxicity 
index of sedative and hypnotic drugs; Paper II presents the occurrence of antipsychotics 
among different manners of death; and in Paper III an attempt is made to assess differences in 
concentrations between acute, acute-on-chronic and chronic intoxications. Further, Paper IV 
presents the impact of sample size on the precision, power and risk for type 1 error of 
postmortem reference concentrations. Using the method presented in paper I-IV, >5 cases in 
each group are needed to reduce the risk of type 1 error (<5%) and >10 cases in each group is 
needed to have a high power (>0.95). It is suggested that a target number of between 20-30 
cases in each group provides a reasonable stability of the reference concentration. 
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1 BACKGROUND 
1.1 WHAT IS AN INTOXICATION? 
According to Stedman’s Medical Dictionary the term intoxication is defined as a synonym to 
the term poisoning. Poisoning in turn refers to the state of being poisoned. More clarity 
results from reviewing the term poison in itself, which is defined as “any substance, either 
taken internally, or applied externally, that is injurious to health or dangerous to life”. A fatal 
intoxication would then be an intake of poison leading to death [1]. 
While the definition of the term poison might seem narrow since, at a first glance, not all 
substances seem harmful to health and life. Things are sadly not so simple; 
“All things are poison, and nothing is without poison, the dosage alone makes it so a thing is 
not a poison."  
The above quote is attributed to Paracelsus (born Theophrastus von Hohenheim), a Swiss 
scientist during the German renaissance. He is credited as the father of toxicology for his 
work on the dose-response relationship [2]. To illustrate his point it is worth noting that even 
water and oxygen, vital to all humans, can result in death if the dose is high enough [3, 4]. 
If anything given in a sufficiently high dose can be a poison, it is of utmost importance to 
know the difference between a harmless and lethal concentration. 
This thesis deals with postmortem reference values of drugs, a standardized method for 
producing them, and their strengths and limitations. 
1.2 GENERAL BACKGROUND 
Since ancient times people have always tried to understand death and the reasons by which it 
occurs. According to Sydney Smith [5], forensic medicine may be defined briefly as 
consisting essentially of that body of medical and paramedical scientific knowledge which 
may be used for the purposes of administration of the law. 
The first known textbook on the investigations of suspect death, Hsi Yüan Lu (lit. the 
“washing away of wrongs”), is of Chinese origin and was published in the thirteenth century 
AD. The text goes into detail regarding a plethora of questions of forensic medicinal 
importance, such as strangulation, drowning and poisoning [5]  
The first known medico-legal expert can be found in ancient Egypt in the form of Imhotep, 
Grand Vizier to King Zozer, 3000 BC [5]. It is known that ancient Egyptians performed 
autopsies and priests made determinations regarding if a death was natural or not [6]. Indeed, 
the epics of Homer lauds the wealth of knowledge regarding poisons gained from the 
Egyptians [5]. The literal meaning of the word autopsy is to see “for one’s self”, to “make a 
personal inspection”. In common usage the term means to dissect a dead body to determine 
the nature of a disease or the cause of death [6]. 
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While poisons and toxins were known in the ancient world, the techniques for detection of 
drugs in cadaveric samples did not start to develop until a couple of hundred years back. 
Considered the founder of modern toxicology, Mathieu Orphila, introduced the analytical 
foundations of the field in his “Treatise in Poisons” published 1814 [5, 7]. However, it took 
until the first half of the twentieth century before forensic toxicology emerged as its own 
branch of the forensic sciences [7].  
Toxicology is the discipline that strives to understand the harmful effects of substances and 
exposures on humans, animals and the environment. Forensic toxicology deals with these 
questions in the legal context, with postmortem toxicology focusing on questions of 
toxicological importance in death investigations. 
1.2.1 Intoxications from a clinical perspective 
From a clinical standpoint, when dealing with intoxications among the living, the treatment of 
a patitent’s symptoms takes precedence over identifying the specific agent involved. General 
therapeutic regimens are used (active charcoal, gastric lavage and/or antidotes to broad 
classes of substances) alongside interventions to stabilize of the patients vital parameters 
(airway, breathing and circulation) [8]. Recognition of a specific toxidrome (collections of 
symptoms typical of intoxication with a specific class of substances) will determine the 
choice of drug treatment and other measures. Specific laboratory testing for the involved 
substances or class of substances are useful as long as it can highlight the need for more 
specific treatment [8, 9]. When the intention is to save lives, the patients symptoms and their 
treatment are most often a higher priority than the identification of the specific substance (and 
concentration) involved. 
1.2.2 Fatal intoxications on the autopsy table 
Fatal intoxications are often difficult to diagnose based on autopsy findings alone. Known 
clinical symptoms might provide information with regard to sample collection and analytical 
strategy, but clinical symptoms can be unspecific or masked by disease. The vast majority of 
poisonings with pharmaceutical drugs will leave no characteristic findings at autopsy. Indeed, 
the most common findings are organ congestion and pulmonary edema, which are quite 
common in all kinds of deaths [10]. 
There are exceptions though. Residues of powder or colored material might indicate tablet or 
capsule remains. Cyanide has a smell of bitter almond. Carbon monoxide poisoning causes a 
cherry red to light red color of the blood and hence also the livores [10]. Noncardiogenic 
pulmonary edema resulting in heavy, enlarged lungs stiff with edema and congestion along 
with froth in the airways is typically found in opioid toxicity deaths [11]. Liver necrosis can 
be the result of paracetamol (acetaminophen) intoxication [12]. The unexpected finding of 
pulmonary embolism in a young subject may raise suspicion of an effect of antipsychotics, 
and in the past of combined oral contraceptives, both known to increase the risk of 
thromboembolism [13, 14], and a massive spontaneous brain haemmorhage, or gastro-
intestinal bleeding may indicate intake of anticouagulants [15]. 
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The above are a few examples, and while they might at first seem specific they can rarely be 
used in isolation to make the correct diagnosis in the vast majority of intoxication cases. 
While the smell of bitter almond is a specific finding, when present, in the case of cyanide 
poisoning one must remember that hydrocyanic acid does not smell like bitter almond to 
many persons [16] and it is possible to have a cyanide poisoning without anyone noting the 
odor of bitter almond since only 40-60% of the population possesses the gene necessary to 
detect the smell [17]. 
In the end, the best way to diagnose intoxications is by correct sampling, toxicological 
analysis and a reasonable evaluation of the results. However, in order to evaluate the 
concentration of a substance in a postmortem cause, the investigator needs to know if the 
concentration is high or low, normal or toxic. To this end, postmortem reference 
concentration data are critical.  
1.2.3 Fatal intoxications from an epidemiological perspective 
The adverse effects of drugs and drug dependence are a worldwide problem. While detailed 
global data are hard to come by, some general trends can be observed. According to a 
recently published article, summarizing 282 causes of death worldwide, unintentional 
poisonings and self-harm (excluding deaths due to firearms) comprised 0.9 and 9.2 per 100 
000 deaths respectively in 2017 [18]. Using a more narrow perspective, a study focusing on 
illicit drugs (opioids, amphetamines, cocaine and cannabis), reported that that the all cause 
mortality comprises an estimated 197,000 deaths annually (including 32,000 due to suicide 
and 69,000 due to opioid overdose mortality) in 2000, a large increase from the 100,000 
estimated deaths in 1990 [19]. 
Regarding substances causing intoxications, the picture is different in different parts of the 
world. Outside the western world intoxication by pesticides dominates in Asia (except 
China), and is second to pharmaceutical drugs in parts of Latin America and sub-Saharan 
Africa [20, 21]. In the USA and Europe non-pesticide (e.g. drugs illicit or not) poisonings 
outnumber poisonings by pesticides among suicides [21]. According to 2015 data from the 
European Centre for Drugs and Drug Addiction (EMCDDA) 17.3 deaths per million 
population are drug induced in the European Union [22], although this figure refers mainly to 
unintentional poisonings indicating that this number would be higher if suicidal intoxications 
were included to a larger extent.  
In the Nordic countries there have been periodical reviews of deaths among drug addicts [23-
26], with the most recent being based on data from 2012 [27]. While the Nordic countries 
have a slightly different panorama of drugs involved, some general trends emerge. The most 
common ascribed main intoxicant, based on the most recent data, is opioids (e.g. 
heroine/morphine, tramadol, codeine) with either benzodiazepines (and related substances) or 
other centrally acting drugs (e.g. amphetamine, GHB and new psychoactive substances) 
following close behind. However, other drugs (i.e. non-illicit drugs or non-scheduled drugs) 
are a very common finding in drug-addict intoxication deaths, comprising 40-73% of all 
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analytical findings. In addition poly-drug use was a common finding with the median number 
of drugs per case (excluding alcohol) being between 4 and 5 in each country, spread among 
both illicit drugs and medicinal drugs [27]. 
Thus, in all cases of fatal intoxications it is important to know which substance(s) have 
caused or contributed. In all death investigations it is equally important to be able to rule out 
intoxication. 
1.3 POSTMORTEM TOXICOLOGY 
In the clinical world, before a drug is released to the market, extensive testing is required. The 
putative drug will first undergo in vitro and then experimental testing in animal models 
before moving on to testing in humans. This testing generates both pharmacokinetic and 
clinical data that can be useful. Over time side effects of various kinds, harmful and not 
harmful, are discovered and can be taken into account in treatment. Hence during clinical 
trials you have access to all this information, together with the specifics in the individual case 
(such as dose given and the status of patient, and during certain phases also the blood drug 
concentration) [28]. 
Next, after the drug has been released on the market, a much larger number of patients will 
receive the drug, and hence more data on side effects will be reported. This information will 
typically be limited to the character and degree of the particular side effect and the dose, but 
not the blood drug concentration [28]. 
In the postmortem setting the situation is often markedly different. Since postmortem 
toxicology deals with deceased subjects there is often a lack of information; it might not be 
known how much of a given drug was ingested (and not even which drugs are suspected) and 
it is not known if the drug produced any side effects. Hospital records might be lacking or 
unavailable. Circumstances surrounding the death might be unknown or unclear. In the worst 
case scenario the only information available is a concentration and a various autopsy 
findings. 
The field of postmortem toxicology has the aim to detect and evaluate effects of detected 
drugs, and thus to provide guidance in a investigation. However, beyond the difference in 
available information in a clinical case in and in a postmortem case, there are several factors 
that make postmortem toxicology an especially challenging field. 
1.3.1 Important pharmacological terms in postmortem toxicology 
When evaluating postmortem concentrations it is important to know how a drug arrives at its 
destination in the body, and to what extent it is present in different tissue compartments as 
related to the blood concentration. 
When a substance is ingested it must move from its site of administration into the central 
compartment (blood). Along the way it must cross membrane barriers (e.g in the 
gastrointestinal tract) and may be subject to metabolic degradation (e.g in the liver). Hence, 
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not all of the ingested substance reaches the blood stream. The fraction of ingested drug that 
reaches the circulation is defined as the bioavailability (F) as follows: 
𝐹 =  𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑖𝑦 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑟𝑒𝑎𝑐ℎ𝑖𝑛𝑔 𝑠𝑦𝑠𝑡𝑒𝑚𝑖𝑐 𝑐𝑖𝑟𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑  
where 0 < 𝐹 ≤ 1. For example, in the case of intravenous administration, all of the drug is 
directly injected into the systemic circulation resulting in F=1. In the case of oral 
administration the F is much more variable, and can be as low as a few percent and as high as 
an intravenous injection depending on the properties of the particular substance [28]. 
A drug is either passively transported across a membrane along a concentration gradient or 
actively transported by various active membrane transport proteins. The ease by which 
substances can cross membranes in the body passively is dependent on multiple factors. 
Many drugs are weak acids or bases and are thus present in both a more lipid soluble non-
ionized form and a less lipid soluble ionized form. The state of drugs ionization is dependent 
on its disassociation constant (pKa) and the pH surrounding the drug as defined by the 
Henderson-Hasselbach equation: 
log [𝑝𝑟𝑜𝑡𝑜𝑛𝑎𝑡𝑒𝑑 𝑓𝑜𝑟𝑚][𝑢𝑛𝑝𝑟𝑜𝑡𝑜𝑛𝑎𝑡𝑒𝑑 𝑓𝑜𝑟𝑚] = 𝑝𝐾𝑎 − 𝑃𝐻 
or stated differently for acids: 
𝑝𝐻 = 𝑝𝐾𝑎 + log 𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑛𝑜𝑛 − 𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
and for bases: 
𝑝𝐻 = 𝑝𝐾𝑎 + log𝑛𝑜𝑛 − 𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  
For example a strong base with a high pKa (e g >8) would be present in the body circulation 
in a predominantly ionized form at normal body pH, decreasing its ability to passively diffuse 
across membranes [28, 29]. 
Apart from pKa, there are two other major factors that determine the permeability of a drug. 
The first is the molecular weight, with larger (heavier) molecules being less able to cross 
membranes. The second is lipophilicity. Lipophilicity is expressed as the partition coefficient 
of n-octanol and water, termed Kp. In general the more lipophilic a molecule is the greater its 
ability to cross membranes [29, 30]. 
With regard to postmortem redistribution (see below) it is also important to know to which 
extent a drug is present in the body (i.e tissues) as compared to the circulation. The volume of 
distribution (Vd) is the amount of fluid that would be required to contain all drug in the body 
at the same concentration as the drug in the circulation: 
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𝑉𝑑 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑏𝑜𝑑𝑦𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑏𝑙𝑜𝑜𝑑 𝑜𝑟 𝑝𝑙𝑎𝑠𝑚𝑎 
A high Vd indicates that most of the drug is present outside of the circulation (either at its site 
of action or in other compartments) [28]. 
1.3.2 Postmortem redistribution 
Prior to the late eighties and early nighties sampling in postmortem cases was collected from 
the heart or from the large vessels, or anywhere else in the body where it was available. In 
many early studies the source of the blood is not specified. The assumption was that a drug 
was evenly diluted in the blood. However, there was a growing body of evidence that things 
were not as simple as they first seemed. 
One early example concerned digoxine, which provoked several questions. A study by 
Vorphal and Coe [31] showed that not only were postmortem concentrations of digoxine in 
general higher than antemortem values (however, in 2 out 11 cases in which femoral blood 
was sampled lower concentrations were found), there were also markedly different 
concentrations depending on where the postmortem blood was sampled. 
In 1990 Prouty and Anderson [32] published a large collection of concentrations from 
different substances, sampled from various parts of the body and at differing times. The study 
found both time and site dependent differences in the postmortem concentrations. Similar 
findings was found in a study by Pounder and Jones published the same year [33], who 
suggested that it might be due to the movement of drugs along a concentration gradient from 
solid organs with high concentrations into the blood. Pounder and Jones named the 
phenomenon “postmortem drug redistribution” and called it “a toxicological nightmare”. 
Subsequent reviews of the subject [30, 34], now called “postmortem redistribution” (PMR), 
confirmed the early hypothesis by Pounder and Jones. In general the extent of postmortem 
redistribution is thought to be dependent on three key factors; proximity to one or more 
reservoir organs, putrefactive changes and the pharmacokinetic properties of the drug 
involved.  
A reservoir organ is a hollow organ (such as the gastrointestinal tract) or an organ with a high 
concentrating power (such as the myocardium, the liver or the lungs). From the tissues of 
high concentration the drug then moves along a concentration gradient to surrounding tissues 
through blood vessels or by way of diffusion. As stated above a proximity to one of these 
organs increases the extent of postmortem redistribution, making blood from the heart, 
thoracic/pulmonary vessels and the inferior vena cava prone to this phenomenon. In addition 
cell death and autolysis, secondary to the putrefactive process, moves drugs previously 
sequestered in the intracellular space (mainly lipophilic bases) to the extracellular space and 
into blood vessels. Apart from factors in the body, the characteristics of each specific drug 
will influence its susceptibility to postmortem redistribution. The disassociation constant 
(pKa) is of importance to determine which drugs are stored in the intracellular space. Drugs 
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with a high volume of distribution (Vd >3 L/kg), which are thus to a large extent stored in 
body tissues, are suggested to a higher degree diffuse back into blood vessels postmortem, 
even if there are notable exceptions (such as paracetamol which has a low Vd but still 
exhibits redistribution). It might also be assumed that the lipophilicity (Kp) is an important 
factor, with the hypothesis that a high Kp increases the likelihood of redistribution [30, 34]. 
However, the extent to which Vd and Kp can explain the postmortem redistribution of a 
substance is variable. In a review by Ferner [35] the association between the ratio of central 
and peripheral blood (as an indication of the extent of postmortem redistribution) and Vd and 
Kp was weak (r = 0.247 and r = 0.035, respectively), showing that postmortem redistribution 
may be difficult to explain. 
The ratio between central blood (such as blood from the heart) and peripheral blood is often 
used as a measure of the extent to which a give substance is prone to redistribution. The 
reasoning being that central blood is closer to reservoir organs (see explanation above), and 
thus more prone to redistribution than peripheral blood, which is more isolated. With regard 
to peripheral blood, femoral blood is the sample of choice as it is the least effected by 
redistribution [30, 34]. A ratio between central and peripheral blood (C/P) of  >3.0 is 
suggested to be indicative of a potential for postmortem redistribution, while a ratio of 1.0 or 
less indicates the opposite. However, this leaves substances between these ratios in a grey 
area [30, 36].   
In order to provide better estimates, other ways to estimate of postmortem redistribution have 
been suggested. McIntyre et al [36, 37] have suggested that the ratio between drug 
concentrations in liver tissue and peripheral blood (L/P) is a more accurate measure, where a 
low ratio (<5) indicates that a substance is not prone to postmortem redistribution, while a 
high ratio would (>20-30) indicates the opposite. As an example hydroxyzine, which has a 
C/P ratio close to 1, has a L/P ratio of ≈14 suggesting a moderate propensity for redistribution 
(based on the L/P ratio but not based on the C/P ratio) which would align more closely with 
the pharmacokinetic aspects of hydroxyzine (liphophilic and a high Vd) [37].  
Another approach is to measure the concentration in a different matrix. The brain has been 
suggested as an alternative, justified by the fact that the brain is anatomically isolated from 
reservoir organs, and has lower metabolic activity and less putrefaction than blood [38]. A 
series of Danish studies [39-42] have explored concentrations and the ratio between femoral 
blood and brain tissue (grey matter from the frontal cortex) and have provided reference 
values for a variety of substances. However, it is important to note that some substances are 
unevenly distributed in the brain [43], introducing a possible source of error unless sampling 
is standardized. 
In summary it can be said that antemortem and postmortem drug concentrations are, in 
general, not the same. A variety of factors contribute to this problem. In order to minimize 
this error sampling is recommended that the sample is collected from a peripheral source of 
blood (femoral blood) and the result being evaluated with care and with regard to 
circumstances of the case and the specifics of the drug in question. 
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1.3.3 Postmortem Interval (PMI) and stability 
In addition to the phenomenon of postmortem drug redistribution, the elapsed time between 
death and sampling is an additional factor to take into consideration. An illustrative example 
of this is a study by Saar et al [44] which showed that there was a marked difference in the 
concentration in peripheral blood of a selection of antipsychotics between the admission to 
the mortuary and the time of autopsy. Indeed, both increases of concentration of over 100% 
(chlorpromazine and olanzapine) and decreases of up to 43% (9OH-risperidone) were shown. 
A similar study by Gerostamoulus et al [45] also showed time dependent changes of 
postmortal concentrations for a variety of substances. Zilg et al [46] additionally showed that 
the postmortem redistribution is more pronounced at longer postmortem intervals. Thus 
postmortem change is not static, but develops over time. This complicates the evaluation of 
postmortem toxicological results, especially when the postmortem interval is unknown. 
Drugs are also not necessarily stable in postmortem blood. Postmortem degradation of drugs 
may occur because of metabolic factors in the body or because of the chemical (in)stability of 
the drug in question [47].  
Metabolic factors include endogenous enzymes, many of which lose their activity not in the 
moment of death but during the first days of the postmortem period [48]. For example, in a 
study regarding postmortem change of drug metabolizing enzymes in rat liver it was found 
that the enzyme NADPH-cytochrome P-450 reductase, which is of key importance in the 
metabolism of many drugs in humans, lost about 60% activity during the first 6h postmortem, 
and over 90% during the first 48 hours [49]. Metabolic factors also include the activity of 
bacteria. A well-known example is that of the nitrobenzodiazepines (nitrazepam, 
flunitrazepam and clonazepam) which are very rapidly metabolized into their 7-amino 
metabolites by the activity of enteric bacteria [50, 51].  
Chemical instability, in which a parent substance and/or a metabolite is degraded or 
reformed, is also a factor that needs to be taken into account. For example, heroin is rapidly 
metabolized to 6-monoacetylmorphine (6-MAM) and then on to morphine. Morphine is in 
turn metabolized in the liver into other substances such as morphine-6-glucoronide (M6G) 
and morphine-3-glucoronide (M3G). In the postmortem setting 6-MAM is unstable in 
alkaline aqueous solutions and the glucoronide metabolites may be hydrolyzed back to 
morphine, making evaluations based on the ratios of metabolites difficult. Amphetamine, 
while in itself stable postmortem, has unstable metabolites which may degrade to form 
amphetamine. The antidepressant fluoxetine has shown to undergo significant degradation in 
room temperature [48]. Volatile compounds (aerosol propellants, anesthetic gases, carbon 
monoxide, ethanol and organic solvents) are unstable when stored at room temperature, 
with significant degradation after a few days of storage [47].  
The impact of both metabolic and chemical factors on the postmortem change of many drugs 
also depends on the temperature of their storage. In general, the postmortem degradation of a 
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drug is due to hydrolysis or oxidation/reduction processes and can be slowed down or halted 
by decreasing their storage temperature [47, 48]. In a stability study of 46 drugs in 
postmortem blood, most of them remained stable at -20 ºC when combined with an added 
preservative (potassium fluoride) [52]. In a study of 30 antipsychotic drugs it was found that 
while the majority was stable, numerous substances were unstable when stored in 4 ºC and 20 
ºC with stability increasing at -20 ºC to -60 ºC storage temperatures [53]. As a general 
recommendation forensic samples should at least be stored in a refrigerator and preferably 
frozen at -20 ºC [54]. However, normally, until found, recently deceased bodies are often 
found in room temperature making reference information about drug stability in room 
temperature particularly important. 
1.3.4 Circumstances of the deceased, of the cause of death and 
resuscitation  
Hospital care, resuscitation and the cause of death in itself can impact the interpretation of 
postmortem drug concentrations. 
In a review by Richardson of the myriad of issues affecting the interpretation of postmortem 
toxicological results, aptly named “Pitfalls in forensic toxicology” [55], the impact of hospital 
care with the treatment with intravenous fluids is discussed. Naturally adding large amounts 
of fluids to the body can dilute, or render tissues devoid of, detectable drug concentrations. 
The pharmacokinetics of critically ill patients with impaired cardiac output, blood pressure 
and ventilation in addition to possible acidosis and the effects of disease, are probably 
different from those seen in study populations seen in most pharmacokinetic studies. Renal 
disease might affect the excretion of a drug and liver disease might affect its metabolism. 
[47]. Resuscitation attempts can also impact postmortem redistribution moving central blood 
more peripherally, and therefore influence the measured concentration of a drug in a 
peripheral blood sample [30, 34]. 
Traumatic deaths with extended blood loss might effect the concentration of drugs, as the 
body tries to adapt to exsanguination, such as the transfer of extravascular fluid into the 
circulation [56, 57]. 
Tolerance, implying various adaptations in the response to a drug upon repeated exposures, 
represent a well-recognized problem in the clinical setting, particularly in the treatment of 
chronic pain. Tolerance can be said to have developed when it is necessary to increase a 
dose to obtain the same effect previously obtained with a lower dose. Development (or loss) 
of tolerance is also a factor that has to be considered in the interpretation of postmortem 
blood concentrations. One example are opioids, which are known to induce substantial 
tolerance when used continuously [55]. It has been shown that blood concentrations alone, 
are not reliable when evaluating possible opioid intoxications [58, 59]. In these cases recent 
previous exposure must be confirmed or excluded in order to evaluate the impact of an 
opioid substance detected. One solution when screening for previous exposure in the 
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timeframe relevant in forensic cases, is hair collected from the vertex or back of the head. 
Circulating substances in the blood are continuously being absorbed by the growing hair 
follicle and incorporated into the bulb of the hair root. A certain proportion of the drug 
incorporated into the growing hair is absorbed from sweat glands surrounding the follicle. 
Segmental hair analysis can thus provide a temporal map of recent substance intake (or lack 
thereof). A lack of exposure (suggesting abstinence) in the innermost hair segment can then 
be used together with the presence of the drug in blood to support a suspicion of 
intoxication as the cause of death [59, 60] 
The disadvantage of using hair to indicate the presence or absence of tolerance by way of 
previous exposure is that tolerance may change in a shorter period of time than that covered 
by segmental hair analysis. One way of approaching this problem would be to use 
pharmacokinetic aspects. In a recent study Selden et al have used the different peak times 
of buprenorphine and its metabolite norbuprenorphine in both blood and urine as an 
indicator for recent intake of drug prior to death [61]. 
1.4 REFERENCE CONCENTRATIONS 
1.4.1 General considerations 
Due to changes in blood drug concentrations that can occur early after death, reference 
information about drug concentrations in living subjects is not a reliable source for 
comparison when evaluating postmortem toxicological results. The forensic community has 
responded to this problem by building reference values from postmortem material. There are 
multiple methods of producing reference concentrations, each with strengths and weaknesses. 
The following section will provide some examples of different types of reference values. 
1.4.2 Case reports and case series 
The most common approach is a descriptive publication of a case or a small series of cases. 
The advantage of this approach is that there is often ample circumstantial information 
available, in the form of medical history and autopsy findings, such as a report of a 
citalopram overdose [62] which includes previous medical history, information from the 
intensive care unit in addition to the toxicological findings. 
One issue with case reports and small series is that in order to gather a body of knowledge 
you need numerous reports, since each report only contains a single or a small group of cases. 
When compiling these findings there can be differences in sample site, matrix used (for 
example plasma, serum or whole blood) and circumstances of the case, which can make 
generalization difficult. Olanzapine can serve as an example of this issue; one study reported 
a concentration in heart blood in a cardiac death [63], another reported an intoxication case in 
heart blood [64] and a third reported an olanzapine related fatality with a blood concentration 
from an unknown sample collection site [65]. While this is only a small sample with a few 
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examples, the sources of potential error and variation can add up over time when building a 
body of reference material based on case reports. 
1.4.3 Descriptive compilations 
One option to increase the number of cases is to extract whole populations from a forensic 
archive (such as a database), for example extracting all cases in which a specific substance 
has been found. The advantage of this approach that it, depending on the size of the archive, 
is easy to present a large number of cases for a variety of substances present in the material. 
Examples of this approach are the studies by Jones and Holmgren [66] and Launiainen and 
Ojanpärä [67], respectively, in which they have used national forensic databases from 
Sweden and Finland. In both studies the upper percentiles of detections in the population 
(90th, 95th and 97.5th) have been presented along with the mean and the median values. This 
type of reference is excellent if you want to know if the concentration of a substance is high 
or not with regard to the general body of detections, but does not tell you wherein that range 
of detections you can find intoxication cases (or normal cases for that matter). 
A similar approach is to extract cases from a large archive, as above, but to also divide them 
according to cause of death. Jones et al. [68] used this approach in a recent study where they 
presented concentrations in deaths attributed to intoxication and subdivided them into single- 
or multi-drug intoxications and presented mean, median and percentiles as above. This 
narrows down the presented population and allows for more precision.  However, with regard 
to multi-drug intoxications it is not always clear if the presented drug in question was a key 
substance (that is actively contributing to the cause of death) or an incidental finding.  
1.4.4 Evaluated compilations 
One way to increase the accuracy of postmortem reference values is to combine the number 
of cases retrieved from a database with an evaluation of each case. The result aims to be a 
“best of both worlds” scenario, combining the review of a case report with the numbers from 
an archive compilation. One example is a review of alprazolam related deaths in Palm Beach 
County [69], which examines all cases in which alprazolam was found between 2001 and 
2003. The study presents concentrations not only in alprazolam intoxication deaths but also in 
death from natural causes, providing a broad reference for evaluation. 
One key advantage of the above study is the reporting of the results in natural death cases; the 
importance of knowing what is normal. As mentioned previously it is equally important to 
know which substances have not contributed to an intoxication death as the reverse. 
Apart from the studies included in this thesis (see Paper I-IV), and previously published work 
from the research group of professor Henrik Druid [70, 71], numerous studies from Denmark 
have used a similar approach [39-42, 72-74]. Both of these groups use a method of evaluating 
database findings to not only present concentrations in intoxication deaths, but also in deaths 
with causes of death other than intoxication, which is if great use to the forensic pathologist. 
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1.4.5 The importance of sample size 
In the scientific literature on postmortem toxicology there is a paucity of information 
regarding the impact of the size of your reference sample on the robustness of the presented 
reference value. 
A review article by Drummer [75] touches the subject and acknowledges its importance, but 
provides no clear data or guidelines. The review of “pitfalls” in forensic toxicology by 
Richardson [55] mention “insufficient experimental or case data” as one of many factors 
impacting the reliability of postmortem reference concentrations, but does not provide 
additional guidance. Other reviews do not mention this aspect at all [10].  
However, common sense suggests that a reference concentration based on many observations 
is more reliable than one based on a few cases. To which extent that reliability varies has so 
far not been clarified. 
1.5 SEDATIVES AND HYPNOTICS 
Regarding sedatives and hypnotics, including anxiolytics (ATC-code N05B and N05C), there 
are a variety of drugs of forensic interest, such as benzodiazepines (e.g. diazepam, 
flunitrazepam and alprazolam), drugs with benzodiazepine-like effect (e.g. zaleplon, 
zolpidem and zopiklon) as well as non-benzodiazepine hypnotics (e.g. propiomazine). 
Benzodiazepines have central nervous system depressant properties. They bind to the 
GABAA receptor, which is present on most neurons in the brain and spinal cord. The GABA 
receptor is heterogenic, i.e. it is built up by five different subunits in a variety of 
configurations that together form the receptor [76]. The benzodiazepines bind to a binding 
site between two different subunits of the GABAA receptor [77]. Upon bindning, 
benzodiazepines modifies the receptor to increase its response to GABA, resulting in an 
increased effect for a given concentration of the neurotransmitter. GABA acts as a CNS 
depressor by hyperpolarizing neurons, increasing their threshold for activation. In a clinical 
setting increased GABA effects protect against seizures, but also causes sedation, promote 
sleep and relieve anxiety [78]. The non-benzodiazepine drugs mentioned above with a similar 
effect (zaleplon, zolipdem and zopiclon) also bind to, and interact with, the subunits of the 
GABAA receptor, although at a site different from benzodiazepines proper [79]. 
Benzodiazepines are one of the most frequently prescribed psychotropic drugs in the world. 
They are of forensic interest because of their abuse potential, especially in combination with 
alcohol and opioids. While there are some minor pharmacokinetic interactions between the 
benzodiazepines and opioids (benzodiazepines being a weak competitive inhibitor of 
CYP3A4, which metabolizes some opioid drugs), there are mainly pharmacodynamic reasons 
for combined use. The abusers typically experience an increased subjective effect of a “high” 
when taking opioids together with benzodiazepines. In addition, opioids and benzodiazepines 
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together produces an increased effect on respiratory depression than either drug acting alone, 
which can be fatal [80].  
According to epidemiological data from the United States benzodiazepines were involved in 
31% of fatal overdoses in 2013. Indeed, during the years 1999 to 2013 the percentage of 
adults filling a benzodiazepine prescription increased from 4.1% to 5.6%; during the same 
period the rate of benzodiazepine related deaths increased from 0.58 to 3.07 per 100 000 
individuals [81]. According to an Nordic epidemiological study on deaths due to fatal 
intoxications among drug abusers from 1997 to 2012, benzodiazepines is an increasingly 
common finding (71-88% of cases as of 2012, with only Iceland breaking the mold at 27%) 
as well as in the number of cases in which it has directly contributed to the death (16.5% of 
Swedish cases 2012) [27]. 
1.6 ANTIPSYCHOTICS 
Antipsychotics (ATC-code N05A) include a variety of drugs to treat schizophrenia. 
Antipsychotics can be roughly divided into two distinct groups of drugs; first generation 
antipsychotics (FGA) and second-generation antipsychotics (SGA). FGAs include, among 
others, phenothiazines (e.g. chlorpromazine and levomepromazine), butyrophenones (e.g. 
haloperidol) and thioxanthenes (e.g. flupentixol). SGAs include, among others, clozapine, 
olanzapine and risperidone [82]. 
All FGAs have a high affinity for the dopamine D2 receptor with studies showing that they 
bind tightly and disassociate slowly [82]. Antipsychotics exert an antagonistic effect on the 
D2 receptor, reducing its signaling. This is important since the postulated hypothesis for the 
pathological mechanism in schizophrenia is increased postsynaptic D2 receptor sensitivity 
[83]. However, a high D2 receptor blockade can lead to cognitive impairment and 
extrapyramidal symptoms (EPS; e.g. dystonia, parkinsonism and tardive dyskinesia). SGAs, 
also known as atypical antipsychotics, have a broader panorama of receptor affinities binding 
not only to D2 receptors but also the serotonin receptors (e.g. 5-HT2A). It has been suggested 
that a higher ratio of binding to the serotonin receptor relative to the dopamine receptor 
explains the increased efficiency and reduced risk of extrapyramidal symptoms of SGAs. 
However, SGAs carries an increased risk of other adverse effects such as weight gain, 
diabetes mellitus and prolonged QTc-interval [82]. 
Globally schizophrenia accounts for 7.4 % of disability-adjusted life years (DALYs, a 
measurement combining premature mortality and disability) caused by mental and substance 
abuse disorders [84]. Patients diagnosed with schizophrenia, the main recipients of 
antipsychotic medication, are also a group of forensic interest. A review showed that patients 
suffering from functional disorders, particularly schizophrenia and major depression, has an 
increased risk of unnatural death [85]. Similarly, a Swedish study of patients suffering from 
schizophrenia between 1973 and 1995 showed a marked increase in mortality for both males 
and females compared to the general population. Interestingly, from a forensic standpoint, 
was that the standardized mortality ratio was increased for both natural and unnatural death 
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(2.8 for males and 2.4 for females), with the highest being suicide (15.7 for males and 19.7 
for females) and unspecified violence (11.7 for males and 9.9 for females) [86]. Regarding 
suicides an international study showed that among suicides in patients suffering from 
schizophrenia, poisoning accounted for 18.6% of the cases, with hanging and jumping being 
more common (28.2% and 25.6% respectively) [87].  
1.7 LITHIUM 
Lithium (ATC-code N05AN01) is a type of antipsychotic medication used in the treatment of 
bipolar disorder. 
Lithium is a true mood stabilizer in the sense that is has both anti-manic antidepressant 
effects, even if the anti-manic effect is more pronounced. However, the specific mechanism 
behind the clinical effect of lithium is not fully known. At the neuronal level lithium inhibits 
excitatory neurotransmission (dopamine and glutamate) and increases inhibitory 
neurotransmission (GABA). However, the picture is more complex since lithium also affects 
intracellular secondary messenger systems, such as adenylyl cyclase and protein kinase C that 
may reduce excitatory neurotransmission. In addition it is has been shown that lithium has 
more general neuroprotective effects in that it reduces oxidative stress, which occurs with 
multiple episodes of depression and mania [88]. While lithium is an effective mood stabilizer, 
not all patients show a response to the treatment and the individual response is variable. It has 
been suggested that the response to lithium has a genetic component, since, for example, 
good responders more often have family history of bipolar disorder and a twin study showed 
better effect of lithium if the co-twin also has bipolar disorder. Recently a study showed a 
locus on chromosome 21 might be involved in the lithium response [89]. 
Of special importance is that evaluation of lithium concentrations in suspected intoxication 
cases is dependent on the mode of intoxication. Studies have proposed three different 
scenarios of lithium intoxication; acute (large intake in the absence of previous lithium 
treatment), acute-on-chronic (large acute intake in the presence of chronic lithium treatment) 
and chronic (progressive lithium toxicity following a change in treatment dose, a decrease in 
renal clearance or due to the presence of certain other medical conditions). Lithium seems to 
have a reverse tolerance relationship, with previous exposure making an individual more 
sensitive to lithium toxicity. It is believed that this phenomenon is related to differing 
baseline levels of lithium saturation in tissues, between the different forms of lithium 
intoxication [90, 91]. 
Globally bipolar disorder accounts for 7.0% of disability-adjusted life years (DALYs, a 
measurement combining premature mortality and disability) caused by mental and substance 
abuse disorders [84]. As with schizophrenia, patients diagnosed with bipolar disorder have an 
increased standardized mortality ratio both with respect to natural, but also unnatural, death 
[92]. International studies show that these patients comprise 2.3–9.6% of all suicidal deaths 
[87, 93-95]. The standardized mortality ratio for suicide in this population is increased 
(SMR 22), even when compared with other 
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(SMR ≈20). In addition, the ratio of suicide attempts to completed suicides is only 5, 
compared to 10-20 in the general population [96]. With regard to the suicide method used 
studies show variable results, indicating that fatal intoxications comprise between 17% and 
53% of all suicides [97]. 
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2 AIMS 
The overall aims of the study were 
• to establish postmortem reference values for selected substances 
• to use the information in our database to answer additional questions of forensic 
interest concerning the studied substances 
• to investigate the number of cases needed to produce stable and reliable reference 
values 
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3 MATERIAL AND METHODS 
3.1 STUDY POPULATION (PAPER I-IV) 
In Sweden a physician must certify all deaths. Depending on the circumstances, this doctor 
should also make a decision as to if the death should be reported to the police. All cases 
where unnatural death (i.e. when some external factor might be involved) cannot be ruled out 
are to be reported to the police. In addition, deaths in which the identity is unclear, in cases of 
suspected medical malpractice and cases of suspected sudden infant death syndrome should 
also be reported to the police. The police in turn will request a forensic autopsy to be 
performed by a Forensic Medicine Department of the Swedish National Board of Forensic 
Medicine. 
The Division of Forensic Medicine of the National Board of Forensic Medicine comprises six 
different Departments of Forensic Medicine from Umeå in the north to Lund in the south. 
Together they perform between 5000 and 5500 autopsies each year [98]. In each case 
samples (femoral vein blood is the sample of choice for drug analysis, when available) are 
taken for toxicological analysis at the national forensic laboratory at the Department of 
Forensic Toxicology and Genetics. The toxicological results for each case together with the 
forensic pathological findings are stored in a central database. At the time of writing the 
database contains about 130,000 autopsy cases, and for most of them there are also 
toxicological results [99]. The included studies in this thesis are all based on data extracted 
from this database, although during somewhat different time periods for different substances. 
3.1.1 Paper I  
The population in paper I is comprised of all cases from the years 1992-2006 in which 
sedative and hypnotic drugs (ATC codes N05B and N05C) and clonazepam (ATC code 
N03AE01) were found in femoral blood. 
3.1.2 Paper II and Paper III 
The populations in paper II and paper III is comprised of all cases from the years 1992-2010 
in which antipsychotics (ATC code N05A), lithium (ATC code N05AN01) and/or 
alimemazine (ATC code R06AD01) were found in femoral blood. 
3.1.3 Paper IV 
Paper IV comprises all cases from the years 1992-2010 in which one or more of 13 
substances (ATC code) were found in femoral blood; alprazolam (N05BA12), amitriptyline 
(N06AA09), carbamazepine (N03AF01), citalopram (N06AB04), nitrazepam (N05CD02), 
olanzapine (N05AH03), oxazepam (N05BA04), oxycodone (N02AA05), phenytoin 
(N03AB02), quetiapine (N05AH04), tramadol (N02AX02), verapamil (C08DA01) and 
zolpidem (N05CF02). 
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3.2 SELECTION OF CONTROL CASES, GROUP C (PAPER I-IV) 
The control group (group C) is made up of cases in which intoxication has not played a role 
in the death. However, not being an intoxication is not the only criterion that has to be met in 
order for a case to be classified as a C-case. As the representation of what constitutes a 
“normal” concentration is important for the selection of intoxication cases (see below), it is of 
utmost importance that the control group is equally reliable. To this end all cases of death in 
the control group also have to reflect that the deceased had an ability to act (i.e. was not 
incapacitated by drugs) at the time of death. Typical examples are hangings and suicidal 
gunshot to the head, which both require active action by the person, hence indicating an 
ability to perform complex tasks immediately prior to death. On the opposite side of the 
spectrum there is death by submersion (drowning) that could be related to at least partial 
incapacitation (e.g. drowning in a bathtub when it cannot be ascertained that the death was a 
result of drugs and the drowning was secondary, or the opposite). 
The cause and manner of death may influence blood drug concentrations. Damage to a 
reservoir organ, and in particular contact between the gastrointestinal tract and the blood may 
cause transferal of high drug concentration to the blood and hence falsely high concentration 
in the blood sampled. Slow exsanguination [56, 57] or hospital care [55] could also impact 
drug concentrations. Hence, such cases are excluded from the C-group. While detailed 
information of this kind is not always available in the forensic database directly, each case 
has to be manually reviewed to screen for these potential sources of error. 
Selecting the cases for the control group is thus a multi-step process; Figure 1 provides a 
schematic overview of the chain of events leading to a confirmed control group case.  
Figure 1. Schematic workflow of the process used to produce postmortem reference 
concentrations. Modified from Paper IV 
.  
Application	of	exclusion	and	inclusion	criteria	(ICD-9)	
Total	detections	of	a	substance	in	database	
Potential	control	cases	 Potential	intoxication	cases	
Manual	review	of	each	case,	with	consensus	among	all	
reviwers	
Group	C	 Group	A	Group	B	
Excluded	
cases	
Excluded	
cases	
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A set of inclusion and exclusion criteria is applied to the broader study population. The 
criteria has been similar in all included papers, however in paper II and paper III, pulmonary 
embolism was added as an exclusion criterion for the C-cases because of the increased risk of 
pulmonary embolism as a side effect of antipsychotic medication [100]. Tables 1 and 2 detail 
the inclusion and exclusion criteria, based on ICD-9 codes with supplements defined by the 
Swedish medico-legal society. The resulting population is made of potential group C cases. 
Table 1: Inclusion criteria for group C based on ICD-9 codes (with supplementary sufficesa) 
Manner of death Cause of death Definition 
  800-959 Trauma and extraneous bodies in upper and 
lower airway 
  410Kb Acute myocardial infarction with rupture 
  441Ab Dissecting aortic aneurysm 
  441Bb, 441Db Ruptured abdominal aortic aneurysm 
  994Bb,c Drowning 
E953   Suicide, hanging, asphyxiation or suffocation 
E955   Suicide, firearms or explosive substances 
E956   Suicide, sharp force injuries 
E958   Suicide, without further specification 
 
a Certain suffices are supplements to the ICD-9 codes defined by the Swedish Medico-legal Society and used by 
the Swedish forensic pathologists to provide more detailed and specific diagnoses 
b Included as inclusion criteria if the number of C-cases were less than 200 
c only drowning by witnessed jumps into water were included.  
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Table 2: Exclusion criteria for group C based on ICD-9 codes (with supplementary sufficesa) Manner	of	death	 Cause	of	death	 Definition			 415Bb	 Pulmonary	embolism			 852L	 Traumatic	subdural	hematoma			 861K	 Bullet	wound	in	thoracic	region			 861M	 Injuries	in	thoracic	internal	organs			 864	 Liver	injury			 869	 Multiple	internal	injuries			 933	 Extraneous	body	in	pharynx	and/or	larynx			 934	 Extraneous	body	in	bronchi	and/or	lung			 940-949	 Burns			 991G	 Hypothermia			 994Bc	 Drowning	E850-E858	 		 Accident,	intoxications	by	drugs	E880-E888	 		 Accident,	fall	E910	 		 Accident,	drowning	E954b	 		 Suicide,	drowning	E958A	 		 Suicide,	collision	with	train	E958B	 		 Suicide,	burning	E958D	 		 Suicide,	frozen	to	death	E960-E969	 		 Murder	E980-E989	 		 Unclear	manner	of	death	a	Certain	suffices	are	supplements	to	the	ICD-9	codes	defined	by	the	Swedish	Medico-legal	Society	and	used	by	the	Swedish	forensic	pathologists	to	provide	more	detailed	and	specific	diagnoses	b	In	paper	II-IV	Pulmonary	embolism	was	an	exclusion	criteria	for	antipsychotics	due	to	the	increased	risk	for	pulmonary	embolism	as	a	side-effect	of	treatment	[14].	c	Death	by	drowning	(994B)	was	excluded,	if	unwitnessed	(most	often	deaths	in	bath	tubs).	
 
Multiple investigators then review the potential group C cases independently, mainly to 
screen for circumstances not immediately apparent from the cause(s) of death in the database. 
For example; the length of any hospital care is checked, and if the stay exceeded several 
hours, the case is excluded since the drug levels then may have dropped or been affected by 
various treatments; cases of drowning and falls are reviewed to remove cases where 
incapacitation cannot be ruled out; trauma cases are reviewed to remove cases with damage 
to reservoir organs and risk of contamination. In addition, cases with unexpectedly high 
concentrations are reviewed to screen for possible misdiagnosed intoxications. 
After independent reviews, the investigators meet and discuss cases where classification 
differ. A case is not included in group C unless all investigators are in agreement that it 
constitutes a control case. Note that each case can be selected into group C for multiple 
substances, if there are detections of several of the substances that are reviewed. 
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3.3 SELECTION OF INTOXICATION CASES, GROUP A AND GROUP B 
(PAPER I-IV) 
Intoxication cases are selected from the study population based on the cause of death 
diagnosis made by the responsible forensic pathologist. As the name suggests the intoxication 
cases are those cases in which death has been primarily attributed to intoxication by drugs 
and/or by alcohol. The cases are extracted from the study population based on a set of 
inclusion criteria based on based on ICD-9 codes with supplements defined by the Swedish 
medico-legal society. The resulting population is made up of potential group A or group B 
cases. 
As with the control cases, selection of the intoxication cases is a multi-step process, Figure 1 
provide a schematic overview of the chain of events leading up to a confirmed group A or 
group B case. After the automatic selection based on ICD-9 codes (see above) each case is 
subject to an independent review by multiple observers. In this review the key substance(s) 
considered responsible for each intoxication case are identified, and the concentration range 
of group C is here used as a guideline to interpretation. Intoxications in which only a single 
key substance has been identified are classified as A-cases. Intoxications with multiple 
substances and/or with an ethanol concentration of  >0.1g/dL are classified as B-cases. Cases 
in which opioid intake might have contributed to the cause of death are excluded as 
concentrations of opioids are difficult to evaluate because of tolerance. As with the control 
group, cases that have been subjected to extended hospital care are also excluded.   
Similarly to the procedure for the C-cases, the investigators meet and discuss cases, where 
discrepant classification has been made. A case is not included in group A or group B unless 
all investigators are in agreement. Note that groups A and B are mutually exclusive, and a 
case can only belong to one of the groups. However, a single case might contribute to group 
B multiple times for different key substances. 
3.4 SELECTION OF LIVING CONTROLS (PAPER I AND II) 
In Paper I and Paper II, living controls were included in addition to the postmortem controls 
described above. We used data gathered from therapeutic drug monitoring and driving under 
the influence cases to gather a suitable control population.  
3.4.1 Therapeutic drug monitoring (TDM) cases (Paper I and II) 
Concentration data was gathered from therapeutic drug monitoring cases at the Department of 
Clinical Pharmacology in Trondheim, Norway. A single sample per patient was used. Cases 
of intentional and unintentional intoxications were excluded, based on the requesting 
physician´s notes. The TDM data was originally presented as mmol/L and were transformed 
to the same unit as the postmortem data (µg/g), approximating that 1ml of serum weighs 1 g. 
Paper I included TDM data collected between 1999 and 2007. 
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Paper II included TDM data from variable time periods for different substances; 1999–2006 
(chlorpromazine, methotrimeprazine, perphenazine, risperidone, sertindole and 
zuclopenthixol), 1999–2007 (alimemazine), 1999–2008 (clozapine), 2000–2005 (quetiapine), 
2000–2006 (flupentixol), 2000–2014 (amisulpride), 2001–2006 (haloperidol and 
ziprasidone), 2005–2006 (aripiprazole) and 2005–2007 (olanzapine). 
3.4.2 Driving under the influence (DUI) cases (Paper I and II)  
Concentration data in cases of driving under the influence analyzed at the department of 
forensic toxicology and genetics in Linköping, Sweden, were compiled. Both studies 
included cases in which relevant substances had been found. Only one sample per person was 
included, thus excluding serial offenders. 
Paper I included DUI case data collected between 1992-2006. 
Paper II included DUI case data collected between 1992-2010. 
3.5 ANALYTICAL CONSIDERATIONS (PAPER I-IV) 
All postmortem samples, as well as the DUI samples mentioned above, were analyzed at the 
Department of forensic toxicology and genetics in Linköping, Sweden. All substances except 
lithium were identified and quantified in the same laboratory. However during the time 
period during which data has been included the methods used and the limit of quantification 
has varied. Details regarding used methods are specified in each paper. In addition, for each 
paper in which method and/or LOQ has been changed during the study period, these 
variations are presented in separate tables. 
For purposes of keeping the concentration data comparable over time, the highest LOQ for 
each substance during the study period has been used as a cut-off. The same “cut-off” LOQ 
was also applied to DUI and TDM data as mentioned above. 
3.5.1 External analysis of Lithium (Paper III) 
Lithium was analyzed externally during the study period (1992-2010) at Department	of	Clinical	Chemistry at Linköping University Hospital (Sweden), at Jönköping Regional 
Hospital (Sweden) as well as the Oslo University Hospital (Norway). 
3.6 FATAL TOXICITY INDEX (PAPER I) 
The fatal toxicity index presented in paper I compares the number of intoxications (i.e. group 
A and B combined) in which a given substance was considered to be contributing to the 
intoxication death with the sales of the substance during a specific time period. 
Sales statistics were defined as the number of defined daily doses (DDD) sold in Sweden 
during the specific time period. A defined daily dose (DDD) is defined as the assumed mean 
dose given to an adult on maintenance therapy for the drugs primary indication.  The DDD 
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data was retrieved from Apotekens Service AB, which, during the study period, administered 
the Swedish prescription database. 
DDD sale statistics were available for the whole study period (1992-2006) for all substances 
except buspirone, clomethiazole, clonazepam, hydroxyzine, propiomazine, zaleplon, 
zolpidem and zopiclone, for which data only were available during 2000-2006.  
3.7 MANNER OF DEATH (PAPER II) 
The manner of death statistics presented in paper II combined the number of cases in which 
the substance was detected, the number of intoxication deaths the substance was detected in 
and the number of intoxication deaths in which the substance was considered as contributing 
stratified on manner of death. 
The external codes (E-series) of ICD-9 were used to define the manner of death as follows: 
Suicides: E950-E959, including suicidal intoxication (E950); accidents: E800-E949, 
including accidental intoxication (E859, E860 and E866); undetermined cases: E980-E989, 
including undetermined intoxication (E980); and homicides: E969-E969, including homicidal 
intoxications (E962). 
These selection criteria were then applied to the study population as a whole and to the 
selected group A and B cases, in order to differentiate the intoxications in which a given 
substance was an incidental finding in which cases it was considered as contributing to the 
cause of death. 
3.8 MODE OF INTOXICATION (PAPER III) 
Based on the classification by Jaeger et al [90] all included lithium cases in group A and 
group B  was classified into acute, acute-on-chronic or chronic intake based on available case 
information. 
3.9 VARIANCE OF MEDIAN, RISK OF TYPE I ERROR AND POWER (PAPER 
IV)  
Due to the non-normal distributions of the observed concentrations only non-parametric 
metrics were applied for the various statistical analyses. For each substance, the impact of the 
size of the data set was studied by randomly drawing (with replacement) N samples from the 
original set of concentrations (groups A, B and C). N varied from 1 up to 50. For each sample 
size (N), the sampling process was repeated 1,000 times. 
The type 1 error (different distributions of concentrations) was estimated by statistically 
comparing the data from the small data set of concentrations with the data from the complete 
set of concentrations using a Mann-Whitney U-test. A p-value below 0.05 was considered to 
be a statistically significant difference and the proportion of such differences was estimated 
for each sample size, N, based on the 1,000 replicates. 
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If a significant difference was observed between the different groups in the original data set 
of concentrations, the power to detect that difference with smaller samples sizes was studied 
in a similar fashion as the type 1 error above. A Mann-Whitney U-test was applied to 
statistically compare the concentrations for the different groups. 
All statistical analyses were performed using the R software v. 3.5.0 [101] 
3.10 ETHICAL CONSIDERATIONS 
The Regional Ethics Review Board in Linköping, Sweden, has approved all included papers 
(No 2012/343-31).  
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4 RESULTS 
4.1 POSTMORTEM REFERENCE VALUES (PAPER I-IV) 
Paper I-III presents postmortem reference values for 41 substances subdivided into two 
intoxication groups (group A and group B) and one control group (group C). Paper IV adds 
additional 7 substances and provides updates from paper I and II to 6 more. In general there is 
an overlap between the two intoxication groups, but the intoxication groups are in general 
significantly different than the control group. While tables with the specific reference values 
for each substance are presented in the different papers, a few examples are shown below 
(Table 3); 
Table 3: Selected reference concentrations (µg/g) adapted from Papers II and IV 
Substance 
(Total detections 
in database) 
Group N 
10th 
percentile 
Median 
90th 
percentile 
P-value 
Citalopram 
(4384) 
A 70 1.09 4.45 21.23 
vs B 
<0.001 
 B 377 0.70 1.40 9.04 
vs C 
<0.001 
 C 916 0.10 0.30 0.70 
vs A 
<0.001 
       
Thioridazine	
(412) A 19 1.34 2.40 4.28 
vs B 
0.16 
 B 40 1.09 1.80 4.05 
vs C 
<0.01 
 C 41 0.20 0.40 0.7 
vs A 
<0.01 
       
Ziprasidone	
(3)	
A - - - - - 
 B 1 - 5.70 - 
vs C 
1.0 
 C 1 - 0.008 - - 
 
4.2 MANNER OF DEATH AND FATAL TOXICITY INDEX (PAPER I-II) 
Paper I presented a fatal toxicity index of sedatives and hypnotics. Flunitrazepam was the 
most common key substance in single intoxication deaths (group A) related to sales. If both 
single intoxications (group A) and multi-substance intoxications (group B) are taken into 
account hydroxyzine was the most common key substance related to sales. 
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Paper II presented the occurrence of antipsychotics according to the manner of death. 
Alimemazine and methotrimeprazine were the most commonly detected antipsychotics across 
all manners of death. However, the most common key substance was clozapine with a high 
proportion of detections in suicidal, uncertain and accidental cases. 
4.3 CONNECTION BETWEEN MODE OF INTOXICATION AND LETHAL 
CONCENTRATION (PAPER III) 
Paper III attempted to investigate whether or not the mode of intoxication affect which 
concentrations should be considered lethal or not. However, due to the paucity of positive 
lithium detections no conclusions could be drawn. Figure 2 illustrates the relationship 
between detections, included intoxication cases and mode of intoxication. 
 
Figure 2. Relationship between total detections, included intoxication cases and mode of 
intoxication. Adpated from paper III   
4.4 SAMPLE SIZE, POWER AND PRECISSION (PAPER IV) 
Paper IV presents data on the impact of sample size on precision, power and the risk of type I 
errors. In general, > 5 cases per group (A/B/C) are needed to reduce the risk of type I error 
below 5% and >10 cases are needed to reach a power of >0.95 when differentiating between 
intoxication (group A and group B) and controls (group C). The general trend is that the 
precision improves as the sample size increases with the rate of improvement decreasing 
Total	detections	in	database	
(124)	
Total	intoxication	cases	
(11)	
Acute	
(1)	
Acute-on-
chronic	
(10)	
Chronic	
(0)	
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rapidly on sample sized above 20-30 cases per group. Figure 3 shows an example of the 
variation of the median across multiple samplings. 
 
 
Figure 3. Boxplot of the distribution of median values when performing replicative sampling 
(n=1000) of sample sizes N=2, 4, 6...50 for the substance Citalopram (Group A cases). The 
reference median value in the complete data set is 4.5. The deviation from the expected 
median decreases as the sample size increases. In the boxplot, the whiskers are 1.5 times the 
interquartile range (IQR), and outliers are shown as circles. Adapted from paper IV. 
 
Paper IV also present the number of detections needed in the in the forensic database in order 
to include a single detection in group A, group B or group C (accounting for detections “lost” 
in application of inclusion/exclusion criteria and manual review). Across all substances an 
average of 5.3 detections were needed in the database to include a single case in a group. As a 
general rule >300 detections would be needed to have a reasonable chance of obtaining 20 
detections in group A, group B and group C in a best case scenario. However based on the 
distribution between the number of cases in different groups in paper I-IV, it can be assumed 
that group A cases are more rare than group C, requiring a larger pool of detections to obtain 
enough cases in each group. 
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5 DISCUSSION 
5.1 WHAT IS CONSIDERED A FATAL INTOXICATION IN THE FORENSIC 
SETTING? 
When using forensic toxicological results to diagnose fatal intoxication, and then using the 
diagnosed fatal intoxications as a basis for what is considered a fatal concentration there is a 
risk of circular reasoning. It would be a mistake to ignore that circular reasoning is a problem 
regarding to postmortem reference values. The question is; How can you diagnose fatal 
intoxication in the absence of forensic toxicological evidence? 
The only way available is to supplement the toxicological interpretation with circumstantial 
information (e.g. police reports, pictures from the scene of the death and medical history) and 
the results from the forensic autopsy (including histological examination of relevant tissues), 
and evaluate the concentration in light of this supplemental information, as is advised in 
reviews of postmortem toxicology [10, 47, 55].  In the present papers, we also present control 
concentrations (group C), which suffers much less from the impact of circular reasoning than 
intoxication cases. Using the concentrations from group C together with the concentrations 
from the intoxication groups and circumstantial information allows for a more balanced and 
secure evaluation. Additionally, the diagnosis of fatal intoxication should be considered a 
diagnosis of exclusion employed only when conflicting causes of death have been ruled out. 
However, the forensic toxicological results are of great importance when diagnosing a fatal 
intoxication, and thus a certain extent of circular reasoning cannot be avoided. 
5.2 THE IMPORTANCE OF PREANALYTIC AND ANALYTIC VARIATION 
When using a reference concentration to evaluate the concentration in an individual case it is 
important to consider the sources of variation.  
A broad spectrum of preanalytic sources of variation is of importance in postmortem forensic 
toxicology [47, 55]. It is difficult to predict the extent to which each of them impact the final 
analytical result. However, with regard to postmortem redistribution Zilg et al [46] have 
shown that the ratio between central and peripheral blood for various substances has a large 
variation (0.2-4.6), which is also dependent on the postmortem interval. While the extent of 
postmortem redistribution varies between substances, between individual cases and with the 
postmortem interval [32, 46] its impact is profound. 
Analytical factors are also of importance, but are often less pronounced than the preanalytical 
factors. Guidelines [102] and published reviews [103] recommend a maximum bias of ± 15-
20% at each concentration and a precision of 15-20%.  
In a sufficiently large group of cases both preanalytical and analytical variations balance each 
other out. However, with regard to an individual case it is important to take both sources of 
variation into account in evaluation. Circumstances of the individual case (e g age, hospital 
care and tolerance) need also be taken into account. 
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5.2.1 Limit of quantification (LOQ) 
One analytic factor that warrants attention is the limit of quantification (LOQ). Depending on 
the LOQ the population of cases, especially in group C (controls), can accrue a bias. 
A study by Jonasson and Saldeen [104], using data from the same database as paper I-IV, 
only included cases in which the femoral blood citalopram concentration was >0.7 µg/g 
(which was considered as indicative of an overdose). Of the 22 included cases in the study, 
citalopram was considered as not contributing to the death in 8 cases. The median 
concentration among those 8 cases was 1.08 µg/g (range 0.7-1.5 µg/g).  Compared to the 
citalopram group C concentrations in paper IV (median 0.3 µg/g) the difference is substantial. 
However, paper IV included all cases allowed by the LOQ (≥ 0.05 µg/g). The high cut-off in 
the study by Jonasson and Saldeen shifted their non-intoxication cases concentration range 
upward. 
Similar shifts, but on a smaller scale, can occur when the differences in LOQ are less 
pronounced. Depending on where the LOQ is in relation to the therapeutic window of a 
substance a number of “normal” concentrations can either be included or excluded, which can 
impact the total concentration distribution of the included cases. 
5.3 THE IMPACT OF SAMPLE SIZE ON THE RELIABILITY OF POSTMORTEM 
REFERENCE VALUES  
While the robust review in the present papers serves to bolster the reliability of the 
classification (i.e. intoxication or control) in our included cases, the issue of low number of 
detections cannot be ignored and must be taken into account in evaluation. Special care must 
be taken with small sample sizes <5, which includes a large amount of available case reports 
and many of the substances included in paper I-IV. 
Of the 41 substances presented in paper I-III, only 12 have >5 cases in each group and only 9 
have >10 cases in each group. Of the 13 substances in paper IV, 9 have >5 cases in each 
group and 6 have >10 cases in each group. As can be seen the amount of cases are often low 
with respect to power and type I error even in the large material used in the present studies. 
As mentioned previously the sample size and power required in postmortem toxicology is 
rarely discussed in the literature. In general it has been stated the sample sizes are often low 
(<10) and that large populations are often needed in order to understand associations between 
causes and effects [75], which is confirmed by the findings of paper IV. 
With regard to precision it is difficult to provide a general guideline. For some substances a 
larger uncertainty might be acceptable, especially if there is little overlap between fatal 
concentrations and controls. However, with small sample sizes it is hard to draw any 
meaningful conclusions with regard to a larger general population. Using citalopram as an 
example, a substance that has been featured in two publications using the same method as in 
paper IV [70, 71], we can see how the reference concentrations have evolved, as more data 
have been available (Table 4). 
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Table 4. Reference concentrations of citalopram (µg/g) across different publications using 
the same method. 
 Druid et al [70] 
(1997) 
 Reis et al [71] 
(2007) 
 Paper IV 
(2019) 
 
n 
10th/50th/90th 
percentilea 
 n 
10th/50th/90th 
percentile 
 n 
10th/50th/90th 
percentile 
Group A 8 3.4/7.0/10.5	  50 1.5/6.5/27	  70 1.09/4.45/21.23	
Group B 13 0.7/1.1/4.7	  243 0.7/1.3/5.9	  377 0.7/1.4/9.04	
Group C 71 0.1/0.6/1.1	  629 0.1/0.3/0.7	  916 0.1/0.3/0.7	
a In groups were n = 4-9 in the paper by Druid et al [70] the lower quartile and upper quartile was used instead 
of the 10th and 90th percentile. 
From a forensic perspective it is of special interest to know how high “normal 
concentrations” (group C) can be and how low lethal (group A) concentrations can go. 
Looking at Table 4 we can see that as the number of included cases increased the 10th 
percentile of group A cases decreased (3.4 µg/g to 1.09 µg/g) and the 90th percentile of group 
C also decreased (1.1 µg/g to 0.7 µg/g). Thus, if case circumstances were otherwise equal, a 
case with a citalopram whole blood concentration of 1.1 µg/g could have been judged as 
potentially normal in 1997 and as a single drug intoxication in 2019. Considering that such a 
large number of cases as we have retrieved for citalopram will not be available for most 
substances, it clear that the concentrations observed for substances with low number of A, B 
and C cases should be used with caution. 
In summary the weight of evidence that is ascribed to a reference value must be based on the 
sample size (i.e to the extent to which the reference concentration can be said to reflect a 
larger population). In the case of small sample sizes there is a risk falsely attributing cases 
when based on postmortem reference concentrations alone, and rather a careful review of the 
background and circumstances surrounding death becomes particularly important. 
5.4 WHAT CAN BE CONSIDERED A “GOOD” REFERENCE IN POSTMORTEM 
TOXICOLOGY? 
What can be considered a good reference in postmortem toxicology depends on the type of 
information it provides.  
As mentioned previously (see section 1.4.3) descriptive compilations, such as the one by 
Launiainen and Ojanperä [67], are proficient at answering whether a given concentration is 
high or low when compared to the total pool of detections. In order for this type of 
compilation to be useful it is important that the LOQ (limit of quantification) is low enough 
to cover a large segment of occurring concentrations. In addition the number of detections 
need to be high enough to provide a basis for generalization.    
In evaluated compilations similar to those presented in this thesis there are three important 
main points to consider; 
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Ø Reliability of the classification. In a postmortem reference there should be a 
high degree of certainty that a case that is presented as an intoxication 
actually is an intoxication (and also that the reverse is true). 
Ø Homogenity of sample collection. Since there are multiple pitfalls with 
regard to postmortem toxicology [55], precautions must be taken to 
minimize their impact. In order to minmize errors samples should all be 
from the same matrix (e.g whole blood) and from the same sample site (e.g 
the femoral vein). Peripheral blood is preferred in order to minimize the 
impact of postmortem redistribution [30, 34]. 
Ø Sample size. A novel finding in Paper IV was the impact of sample size on 
the reliability of the presented postmortem reference values. Thus in order 
to draw reliable conclusions from avaliable reference material a high 
sample size is prefered. Based on our data >10 cases in each group are 
strongly recommended and 20-30 are preferable. While there is no higher 
limit on the number of cases that can be included, the added benefit of 
additional cases decreases >30, and the importance of added precision in the 
reference concentrations must be weighted against the impact of other 
sources of error that are more difficult to control for (e.g postmortem 
interval and analytical variation) [10, 55]. 
If the above points are satisfactorily fulfilled reference compilations using similar methods to 
that which is presented in this thesis can be deemed reliable. As an example, the reference 
concentrations of thioridazine and ziprasidone (see Table 3) are both equally reliable with 
regard to the first two points, but the lack of sample size makes the resulting reference 
concentration of ziprasidone more unreliable.  
Compared to descriptive compilations the method used in this thesis are better at providing 
answers to the range of concentrations that can be considered normal and fatal (i.e. how high 
concentrations can still be considered “normal” and how low concentrations can be 
considered fatal). 
With the data on sample size provided in Paper IV caution must be taken when using case 
reports and small case series as a basis for evaluation, since a majority of these include <5 
cases in total. While both the reliability of the case classification and sample collections 
might be adequate, the low number of cases introduces a large degree of uncertainty to the 
reference concentration. Thus the case can be made that the primary value of case reports 
might not be the concentrations presented, and focus should perhaps be on other aspects such 
as reporting novel interactions, side effects or unexpected circumstances [105]. Case reports 
can also function as a starting point for further research [106]. 
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5.5 STRENGTHS 
While the field of postmortem toxicology comprises a complicated problem with regard to 
evaluation, the approach to reference values used in the included papers features several 
strengths. 
The size of the database from which the study population is derived is large and features 
information from both forensic pathology and forensic toxicology. The large size of the study 
populations allows for application of strict selection criteria. It is equally important that both 
the intoxication cases and control cases are correctly identified, and hence by starting with a 
large material, there is more opportunities for excluding cases whenever the circumstances 
are not clear cut to minimize sources of error. While other studies use a similar approach [39-
42, 72-74], there are slight differences in the process of case selection, with the present papers 
using multiple reviewer process and consensus meetings before inclusion as well as a focus 
on the immediate cause of death and the exclusion of incapacitation in the postmortem 
control cases. 
Another strength is that the autopsy sampling method is standardized and only femoral blood 
is included, reducing the problem with postmortem redistribution. 
Lastly the process used and the wealth of available information in each case enables a high 
confidence in the classification of cases, both in cases of intoxication and controls. The access 
to the autopsy report in all cases allows us to e.g. check the extent of possible contaminating 
injuries and to rule out competing cause of death in unclear cases. Similarly, the access to the 
police reports and, in a proportion of the cases, medical records allows for scrutinizing the 
circumstances surrounding death. 
5.6 LIMITATIONS  
As mentioned above there is a risk that circular reasoning impacts the generation of reference 
values. Having said that, this problem is reduced with the application of the strict inclusion 
and exclusion criteria and manual review. 
One disadvantage of the process is that it is time consuming. Using multiple rounds of 
evaluation including a multiple reviewer consensus requires both time and manpower. 
Another disadvantage of this approach is that it requires many detections of a substance to 
reach a significant number of certifiable non-intoxications deaths and intoxication cases.  
In addition it is important to remember that all postmortem cases in the present papers are 
extracted from a forensic pathological population. Thus there are factors of age, sex and 
burden of disease that may not be applicable to the general population. This might, in turn, 
impact the susceptibility to the adverse effects of ingested substances that could affect the 
resulting postmortem reference concentrations. 
Lastly it is important to remember that there is a multitude of factors that may influence the 
blood drug concentration in each particular case [10, 47, 55]. Thus it is important to evaluate 
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postmortem concentrations not only with regard to reference concentrations, but also with 
regard to the unique circumstances in each case.  
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6 CONCLUSIONS 
The method used to provide postmortem reference in postmortem femoral blood was 
presented along with suggested reference values for a total of 48 substances, providing 
support to the forensic pathologist in evaluation of postmortem toxicological results. 
Novel information with regard to the relationship between sample size and precision, power 
and type I error was presented based on our data. These results underscore the importance of 
compilation and evaluation of sufficiently large populations in order to generate reliable 
reference concentrations. 
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7 FUTURE DIRECTIONS 
As has been demonstrated by the calculations done in paper IV there is a need for updating 
reference concentrations for drugs where previous evaluations were based on small sample 
sizes. A target number would be a minimum of 20-30 cases in each group. However, as can 
be seen in paper IV, the number of detections needed to reach the desired number included is 
high. Higher degree of international cooperation in pooling toxicological data for research 
purposes could greatly aid the quality of postmortem reference concentrations. 
Our current reference values do not take the chiral structure [107] of substances into account. 
For example, the concentrations of citalopram in paper IV are the total citalopram 
concentration, which is in turn is a racemate of R-citalopram and escitalopram. Escitalopram 
has been shown to be responsible for the serotonin reuptake and antidepressant effect of 
citalopram. In addition it has been shown that escitalopram alone has better effect than the 
same amount of escitalopram given in combination with R-citalopram. In effect R-citalopram 
inhibits the effect of escitaopram [108].  R-citalopram and escitalopram also seem to have 
different impact on the QTc interval [109]. Thus it may be that the concentration that can be 
considered normal and toxic might be different for escitalopram and total citalopram, which 
is not reflected in our current reference values. While the department of forensic toxicology 
does not yet use a chiral method for citalopram, introduction of such a method might generate 
data that may improve the interpretation of citalopram.  
Paper I-IV only takes into account the parent compound of the studied substances. A previous 
study by Reis et al [71], using the same method for obtaining postmortem reference values as 
in the present papers, presented ratios of metabolite to parent compound in intoxications and 
controls. However, it is well known that active metabolites can and do play a role in the 
pharmacologic response and toxicity [110, 111]. One way to approach this could be to add 
concentrations of parent substance and metabolite together, as has been done with nitrazepam 
in paper II and IV (although done there for reasons of postmortem metabolism). However, 
when using the current reference values, active metabolites must be taken into account on an 
individual case-by-case basis. 
The results from Paper III could not provide evidence for the link between the mode of 
lithium intoxication and the resulting intoxication concentrations. However, the underlying 
question of changes at a substances site of action that impact at which concentrations side 
effects occur is interesting. Because of tolerance [55] the concentration measured in the blood 
might not be the best measure of the effects of a drug. As an example, the respiratory 
depression caused by opioids is the result of action at respiratory control centers in the central 
nervous system [112]. Future research could combine results from hair analysis [60, 113, 
114] and drug concentrations at its site of action to provide more accurate information when 
evaluating the effect of a particular intake of a drug. 
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It has been stated that 15-30%, and in some cases up to 95%, of drug metabolism and drug 
response are attributed to genetic factors [115]. From a forensic viewpoint differences in 
metabolic ability (i.e. fast vs. slow metabolizers) are of importance when determining the 
manner of death and difference in drug targets and drug transport can be of importance for 
determining fatal intoxication as a cause of death [116]. Differences in pharmacodynamic 
response to a given drug based on genetic factors will of course impact which concentrations 
that can be considered toxic and normal in different genetic populations. Thus, a future 
approach could be to try to differentiate cases of intoxication according to genetic 
polymorphisms. 
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